Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lowest Effective Dose of Drospirenone/Estradiol for Vasomotor Symptoms
NCT00446199Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of drospirenone and estradiol in vasomotor symptoms (4 arms), sponsored by Bayer. Primary endpoints: Change From Baseline in Weekly Frequency of Moderate to Severe Hot Flushes at 12 weeks and Change From Baseline in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes at 12 weeks. Started Mar 2007; status: completed.
02
Drugs
drospirenoneestradiol
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00446199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00446199.